Valneva lowers 2025 financial outlook due to loss of Ixchiq vaccine marketing
Source: SeekingAlpha
2025-10-06 12:37:53 ET
More on Valneva
- Valneva Outlook: Safety Blow To Ixchiq And Valuation Concerns
- Valneva SE 2025 Q2 - Results - Earnings Call Presentation
- Valneva SE (VALN) Q2 2025 Earnings Call Transcript
- Valneva suspended from marketing chikungunya shot in U.S. over safety concerns
- Valneva reports 1H results; reaffirms FY outlook
Read the full article on Seeking Alpha
For further details see:
Valneva lowers 2025 financial outlook due to loss of Ixchiq vaccine marketing
Valneva SE
NASDAQ: VALN
VALN Trading
6.78% G/L:
$11.495 Last:
15,383 Volume:
$11.27 Open:
VALN Latest News
October 01, 2025 04:20:00 pm
Ongoing Valneva SE (VALN) Investigation: Protect Your Rights - Contact Levi & Korsinsky
VALN Stock Data
$798,793,290
73,508,485
N/A
10
N/A
Biotechnology & Life Sciences
Healthcare
FR
Lyon
